| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.57▼ | 1.57▲ | 1.58▼ | 1.56▲ | 1.58▲ |
| MA10 | 1.57▲ | 1.59▼ | 1.59▼ | 1.59▼ | 1.50▲ |
| MA20 | 1.57▲ | 1.59▼ | 1.60▼ | 1.61▼ | 1.49▲ |
| MA50 | 1.59▼ | 1.57▲ | 1.55▲ | 1.52▲ | 2.48▼ |
| MA100 | 1.58▼ | 1.57▲ | 1.58▼ | 1.49▲ | 5.74▼ |
| MA200 | 1.57▲ | 1.59▼ | 1.59▼ | 2.28▼ | 6.58▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.005▼ | -0.005▼ | -0.007▼ | 0.112▲ |
| RSI | 46.223▼ | 46.615▼ | 49.156▼ | 50.752▲ | 44.080▼ |
| STOCH | 69.444 | 29.646 | 47.497 | 41.088 | 43.229 |
| WILL %R | -50.000 | -63.636 | -60.870 | -47.368 | -59.898 |
| CCI | 75.000 | -60.185 | -42.266 | 6.943 | 21.665 |
|
Thursday, August 14, 2025 04:22 PM
MacroGenics (MGNX) delivered earnings and revenue surprises of +3.39% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
|
|
Thursday, August 14, 2025 01:38 PM
ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the ...
|
|
Thursday, August 14, 2025 08:21 AM
Source: Analyst estimates for the quarter provided by FactSet.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.60 | 1.63 | 1.535 | 1.58 | 530,577 |
| 14/08/25 | 1.59 | 1.65 | 1.525 | 1.62 | 489,405 |
| 13/08/25 | 1.46 | 1.67 | 1.46 | 1.66 | 530,683 |
| 12/08/25 | 1.47 | 1.50 | 1.43 | 1.47 | 435,107 |
| 11/08/25 | 1.55 | 1.58 | 1.46 | 1.47 | 493,985 |
| 08/08/25 | 1.64 | 1.64 | 1.50 | 1.54 | 221,900 |
| 07/08/25 | 1.62 | 1.6236 | 1.54 | 1.61 | 256,381 |
| 06/08/25 | 1.71 | 1.71 | 1.59 | 1.61 | 303,863 |
| 05/08/25 | 1.62 | 1.715 | 1.58 | 1.69 | 590,110 |
| 04/08/25 | 1.60 | 1.665 | 1.531 | 1.64 | 291,557 |
|
|
||||
|
|
||||
|
|